Reference
- Gabert, J., Beillard, E., Bi, W., Pallisgaard, N., Gottardi, E., Cazzaniga, G., et al. (2000) European standardization and quality control program of real time quantitative RT-PCR analysis of fusion gene transcripts for minimal residual detection in leukemia patients. ASH 2000, Poster 1343. http://194.214.97.12/mrd_leukemia/ ash2000. htm
- Merx, K., Muller, M.C., Kreil, S., Lahaye, T., Paschka, P., Schoch, C., et al. (2002) "Early reduction of BCR—ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha", Leukemia, 16, 1579— 1583.
- Wu, C.J., Neuberg, D., Chillemi, A., McLaughlin, S., Hochberg, E.P., Galinsky, I., et al. (2002) "Quantitative monitoring of BCR/ ABL transcript during STI-571 therapy", Leukemia & Lymphoma, 43, 2281 — 2289.
- Kantarjian, H.M., Talpaz, M., Cortes, J., O'Brien, S., Faderl, S., Thomas, D., et al. (2003) "Quantitative Polymerase Chain Reaction Monitoring of BCR-ABL during Therapy with Imatinib Mesylate (STI571; Gleevec) in Chronic-Phase Chronic Myelogenous Leuke-mia", Clin. Cancer Res., 9, 160 — 166.
- Wang, L., Pearson, K., Ferguson, J.E., Clark, R.E. (2003) "The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukemia", Br. J. Haematol., 120, 990–999.
- Muller, MC., Merx, K., Weibetaer, A., Kreil, S., Lahaye, T., Hehlmann et al. (2002) "Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization", Leukemia, 16, 2395–2399.
- Van der Velden, V.H.J., Hochhaus, A., Cazzaniga, G., Szczepanski, T., Gabert, J., Van Dongen, J.J.M. (2003) "Detection of minimal residual disease in hematological malignancies by real-time quanti-tative PCR: principles, approaches, and laboratory aspects", Leukemia, 17, 1013 — 1034.